In most cancer types there is a need for new and better biomarkers to guide treatment of the individual cancer patient.These biomarkers comprise markers for early detection of disease, markers for prognostic stratification, predictive markers and markers for patient surveillance.We have recently established the Sino-Danish Breast Cancer Research Centre with the objective to identify, evaluate and clinically validate candidate biomarkers for the prediction of treatment benefit/response to routine chemotherapy and routine endocrine treatment in breast cancer, thereby allowing for individualized treatment of breast cancer patients.It is the hypothesis, that several genes may be modified by mutations, amplifications, insertions or deletions in breast cancer tissue and that these genetic changes together results in either sensitivity or resistance to chemotherapy and/or endocrine treatment.We have chosen to focus our efforts on molecular mechanisms involved in resistance to the two most used chemotherapeutic drugs in breast cancer:anthracyclines and taxanes, and to aromatase inhibitors.We will present results from our first studies which shows that the integration ofTIMP-1 with HER2 or TOP2A gene aberrations more accurately identifies patients who benefit from anthracycline containing chemotherapy (CEF) as compared to non-anthracycline containing chemotherapy (CMF)than these marker do individually.In particular, the combination of TIMP-1 immunoreactivity and TOP2A DNA aberrations was found to be a highly significant predictor of benefit from CEF compared to CMF (Pinteraction <0.0001for Invasive Disease-Free Survival and 0.004 for Overall Survival in adjuvant treatment of high risk breast cancer patients.